Recursion director plans sale of 30K RXRX shares
RECURSION PHARMACEUTICALS, INC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
RECURSION PHARMACEUTICALS, INC. (RXRX) director Blake Borgeson has filed a Form 144 indicating an intent to sell 30,000 Class A shares of Recursion through Fidelity Brokerage Services LLC, with an approximate aggregate value of $100,200. The shares were originally acquired on 09/19/2017 as Founders Shares received as compensation. The notice also lists prior Rule 144 sales over the last three months.
Key Figures
Key Terms
Rule 144 regulatory
attorney-in-fact regulatory
aggregate sale price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing for RXRX disclose about Blake Borgeson?
AI-generated analysis. How Rhea-AI works. Not financial advice.